Quick Answer
Verrica Pharmaceuticals Inc. reported Total Revenue of $35.58 million for the year ending 2025.
- Verrica Pharmaceuticals Inc. showed an increase of +370.2% in Total Revenue from 2024 to 2025.
- This data is from Verrica Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on March 11, 2026.
- XBRL data for this metric is available from 2021 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $12.00 million | Q2 2021: $0.00 | Q3 2021: $0.00 | Q1 2022: $431.0 thousand | Q2 2022: $214.0 thousand | Q3 2022: $8.32 million | Q1 2023: $37.0 thousand | Q2 2023: $182.0 thousand | Q3 2023: $2.92 million | Q1 2024: $3.83 million | Q2 2024: $5.18 million | Q3 2024: -$1.78 million | Q3 2024: -$1.78 million | Q1 2025: $3.44 million | Q2 2025: $12.70 million | Q3 2025: $14.34 million.
- Over the full 6 years of available data (2021 to 2025), Verrica Pharmaceuticals Inc.'s Total Revenue has grown by 196.5%.
- Historical annual values: Fiscal year 2025: $35.58 million | Fiscal year 2024: $7.57 million | Fiscal year 2024: $7.57 million | Fiscal year 2023: $5.12 million | Fiscal year 2022: $9.03 million | Fiscal year 2021: $12.00 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: